Xponance Inc. Purchases 1,149 Shares of Stryker Co. (NYSE:SYK)

Xponance Inc. boosted its position in shares of Stryker Co. (NYSE:SYK) by 2.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,306 shares of the medical technology company’s stock after acquiring an additional 1,149 shares during the period. Xponance Inc.’s holdings in Stryker were worth $15,664,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ninety One North America Inc. raised its stake in Stryker by 2.9% during the 4th quarter. Ninety One North America Inc. now owns 18,545 shares of the medical technology company’s stock worth $5,553,000 after acquiring an additional 522 shares during the period. OLD Second National Bank of Aurora raised its position in shares of Stryker by 0.9% during the fourth quarter. OLD Second National Bank of Aurora now owns 8,188 shares of the medical technology company’s stock valued at $2,452,000 after buying an additional 75 shares during the last quarter. Peterson Wealth Services raised its position in shares of Stryker by 2.2% during the fourth quarter. Peterson Wealth Services now owns 12,098 shares of the medical technology company’s stock valued at $3,623,000 after buying an additional 255 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its position in shares of Stryker by 3.0% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 10,979 shares of the medical technology company’s stock valued at $3,295,000 after buying an additional 322 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of Stryker by 7.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 34,107 shares of the medical technology company’s stock valued at $10,214,000 after buying an additional 2,468 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 2.6 %

NYSE SYK opened at $327.45 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average of $350.34 and a two-hundred day moving average of $312.14. The firm has a market capitalization of $124.58 billion, a price-to-earnings ratio of 39.69, a PEG ratio of 2.71 and a beta of 0.89. Stryker Co. has a 52 week low of $249.98 and a 52 week high of $361.41.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. The company had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. Stryker’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.00 earnings per share. On average, analysts predict that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is currently 38.79%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SYK. Citigroup lifted their price objective on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada lifted their price objective on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research report on Monday. Wells Fargo & Company lifted their price objective on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Finally, TD Cowen raised their target price on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $340.45.

Insider Activity

In other news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.